Eidos Therapeutics Appoints William Lis to Board of Directors

SAN FRANCISCO, Dec. 06, 2018 (GLOBE NEWSWIRE) — Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large unmet need in transthyretin (TTR) amyloidosis…

About Globe Newswire

Nasdaq Globenewswire on NEWSTAGE
View all posts by Globe Newswire →

Leave a Reply

Your email address will not be published. Required fields are marked *